NEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (OTC QB: TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications has reported financial results for the quarter ended March 31, 2016.
“Based on input from various sources and the strong interest of several clinical sites the initial focus now for our lead compound, SM-88, is to initiate a clinical study in prostate cancer. We expect to be able to announce further details shortly and we are preparing for other studies including those in breast and pancreatic cancers,” said Steve Hoffman, President and Chief Executive Officer.
